CNS Cluster Addiction Drug Development Pipeline Review, 2017

  • ID: 4258942
  • Report
  • Region: Global
  • 150 Pages
  • GBI Research
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • BioCorRx Inc
  • Curemark LLC
  • Hager Biosciences LLC
  • Kyowa Hakko Kirin Co Ltd
  • P2D Bioscience
  • MORE

CNS Cluster Addiction Drug Development Pipeline Review, 2017

Summary

This report provides an overview of the CNS Clusters pipeline landscape. The report provides comprehensive information on the therapeutics under development, and key players involved in therapeutic development for Alcohol Addiction, Drug Addiction, Nicotine Addiction, Opium (Opioid) Addiction and features dormant and discontinued projects.

Alcohol addiction refers to a psychological and physical dependency on alcohol. Symptoms include decreased involvement in extracurricular activities, depression, restlessness, inability to control drinking and violent behavior. There are a total of 38 products in development for this indication, by 29 companies and five academic institutions. Key companies operating in this pipeline space include Abbvie, Astraea Therapeutics, Lochola Research and SK Biopharmaceuticals.

Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. There are a total of 67 products in development for this indication, by 38 companies and 16 academic institutions. Key companies operating in this pipeline space include Astraea Therapeutics, Addex therapeutics, The University of Kansas, Embera NeuroTherapeutics, InterveXion Therapeutics, Omeros, Opiant Pharmaceuticals and Orexigen Therapeutics.

Nicotine addiction also called tobacco dependence is an addiction to tobacco products caused by the drug nicotine. There are a total of 19 products in development for this indication, by 13 companies and 5 academic institutions. The majority of companies are developing single pipeline program in this space, while Omeros are developing two.

Finally, opioid addiction develops after using opioids regularly for a period of time. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers known as endorphins). There are a total of 33 products in development for this indication, by 23 companies and three academic institutions. Key companies operating in this pipeline space include Indivior, INSYS Therapeutics, Omeros, Pfizer and Zynerba Pharmaceuticals.

There is a substantial degree of overlap between these indications in terms of the types of molecular target which are being studied. The mu and kappa-opioid receptors are the dominant molecular target across alcohol, drug and opioid addiction, and other neurotransmitter receptors such as the cannabinoid and dopamine receptors are common molecular targets across the three. In contrast, while such neurotransmitter receptors are present in the nicotine addiction pipeline, the opioid receptors are not, and the dominant molecular target is the orexin receptor type 1.

Scope

  • Which companies are the most active within the pipeline for addiction therapeutics?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in the field of addiction therapeutics?

Reasons to buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • BioCorRx Inc
  • Curemark LLC
  • Hager Biosciences LLC
  • Kyowa Hakko Kirin Co Ltd
  • P2D Bioscience
  • MORE

1. Report Guidance

2. Executive Summary

3. Introduction

4. CNS Cluster Addiction Report Coverage

  • Alcohol Addiction - Overview
  • Drug Addiction - Overview
  • Nicotine Addiction - Overview
  • Opium (Opioid) Addiction - Overview

5. Therapeutics Development

  • Alcohol Addiction
  • Drug Addiction
  • Nicotine Addiction
  • Opium (Opioid) Addiction

6. Therapeutics Assessment

  • Alcohol Addiction
  • Drug Addiction
  • Nicotine Addiction
  • Opium (Opioid) Addiction

7. Companies Involved in Therapeutics Development

  • Alcohol Addiction
  • Drug Addiction
  • Nicotine Addiction
  • Opium (Opioid) Addiction

8. Dormant Projects

  • Alcohol Addiction
  • Drug Addiction
  • Nicotine Addiction
  • Opium (Opioid) Addiction

9. Discontinued Products

  • Alcohol Addiction
  • Drug Addiction
  • Nicotine Addiction
  • Opium (Opioid) Addiction

10. Product Development Milestones

  • Alcohol Addiction
  • Drug Addiction
  • Nicotine Addiction
  • Opium (Opioid) Addiction

11. Appendix

  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation

List of Tables

  • Number of Products under Development for Alcohol Addiction
  • Number of Products under Development by Companies, Alcohol Addiction
  • Number of Products under Development by Universities/Institutes, Alcohol Addiction
  • Products under Development by Companies, Alcohol Addiction
  • Products under Development by Universities/Institutes, Alcohol Addiction
  • Number of Products under Development for Drug Addiction
  • Number of Products under Development by Companies, Drug Addiction
  • Number of Products under Development by Universities/Institutes, Drug Addiction
  • Products under Development by Companies, Drug Addiction
  • Products under Development by Universities/Institutes, Drug Addiction
  • Number of Products under Development for Nicotine Addiction
  • Number of Products under Development by Companies, Nicotine Addiction
  • Number of Products under Development by Universities/Institutes, Nicotine Addiction
  • Products under Development by Companies, Nicotine Addiction
  • Products under Development by Universities/Institutes, Nicotine Addiction
  • Number of Products under Development for Opium (Opioid) Addiction
  • Number of Products under Development by Companies, Opium (Opioid) Addiction
  • Number of Products under Development by Universities/Institutes, Opium (Opioid) Addiction
  • Products under Development by Companies, Opium (Opioid) Addiction
  • Products under Development by Universities/Institutes, Opium (Opioid) Addiction
  • Number of Products by Stage and Target, Alcohol Addiction
  • Number of Products by Stage and Mechanism of Action, Alcohol Addiction
  • Number of Products by Stage and Route of Administration, Alcohol Addiction
  • Number of Products by Stage and Molecule Type, Alcohol Addiction
  • Number of Products by Stage and Target, Drug Addiction
  • Number of Products by Stage and Mechanism of Action, Drug Addiction
  • Number of Products by Stage and Route of Administration, Drug Addiction
  • Number of Products by Stage and Molecule Type, Drug Addiction
  • Number of Products by Stage and Target, Nicotine Addiction
  • Number of Products by Stage and Mechanism of Action, Nicotine Addiction
  • Number of Products by Stage and Route of Administration, Nicotine Addiction
  • Number of Products by Stage and Molecule Type, Nicotine Addiction
  • Number of Products by Stage and Target, Opium (Opioid) Addiction
  • Number of Products by Stage and Mechanism of Action, Opium (Opioid) Addiction
  • Number of Products by Stage and Route of Administration, Opium (Opioid) Addiction
  • Number of Products by Stage and Molecule Type, Opium (Opioid) Addiction
  • Alcohol Addiction - Pipeline by AbbVie Inc
  • Alcohol Addiction - Pipeline by Addex Therapeutics Ltd
  • Alcohol Addiction - Pipeline by Adial Pharmaceuticals LLC
  • Alcohol Addiction - Pipeline by Astraea Therapeutics LLC
  • Alcohol Addiction - Pipeline by BioCorRx Inc
  • Alcohol Addiction - Pipeline by Bionex Pharmaceuticals LLC
  • Alcohol Addiction - Pipeline by Bioprojet SCR
  • Alcohol Addiction - Pipeline by Cerecor Inc
  • Alcohol Addiction - Pipeline by Chronos Therapeutics Ltd
  • Alcohol Addiction - Pipeline by Corcept Therapeutics Inc
  • Alcohol Addiction - Pipeline by Curemark LLC
  • Alcohol Addiction - Pipeline by Eli Lilly and Company
  • Alcohol Addiction - Pipeline by Ethypharm SA
  • Alcohol Addiction - Pipeline by Euthymics Bioscience Inc
  • Alcohol Addiction - Pipeline by H. Lundbeck A/S
  • Alcohol Addiction - Pipeline by Heptares Therapeutics Ltd
  • Alcohol Addiction - Pipeline by Indivior Plc
  • Alcohol Addiction - Pipeline by Kinnov Therapeutics SAS
  • Alcohol Addiction - Pipeline by Kyorin Pharmaceutical Co Ltd
  • Alcohol Addiction - Pipeline by Lohocla Research Corp
  • Alcohol Addiction - Pipeline by Omeros Corp
  • Alcohol Addiction - Pipeline by Pfizer Inc
  • Alcohol Addiction - Pipeline by Savant HWP Inc
  • Alcohol Addiction - Pipeline by SK Biopharmaceuticals Co Ltd
  • Alcohol Addiction - Pipeline by Tonix Pharmaceuticals Holding Corp
  • Alcohol Addiction - Pipeline by VM Discovery Inc
  • Alcohol Addiction - Pipeline by XenoPort Inc
  • Alcohol Addiction - Pipeline by Zynerba Pharmaceuticals Inc
  • Drug Addiction - Pipeline by Addex Therapeutics Ltd
  • Drug Addiction - Pipeline by Aelis Farma SAS
  • Drug Addiction - Pipeline by Aphios Corp
  • Drug Addiction - Pipeline by Astraea Therapeutics LLC
  • Drug Addiction - Pipeline by BioCorRx Inc
  • Drug Addiction - Pipeline by Cerecor Inc
  • Drug Addiction - Pipeline by Chiesi Farmaceutici SpA
  • Drug Addiction - Pipeline by Curemark LLC
  • Drug Addiction - Pipeline by Embera NeuroTherapeutics Inc
  • Drug Addiction - Pipeline by F. Hoffmann-La Roche Ltd
  • Drug Addiction - Pipeline by Foresee Pharmaceuticals LLC
  • Drug Addiction - Pipeline by Heptares Therapeutics Ltd
  • Drug Addiction - Pipeline by Immunovaccine Inc
  • Drug Addiction - Pipeline by Indivior Plc
  • Drug Addiction - Pipeline by InterveXion Therapeutics LLC
  • Drug Addiction - Pipeline by Intra-Cellular Therapies Inc
  • Drug Addiction - Pipeline by Kyorin Pharmaceutical Co Ltd
  • Drug Addiction - Pipeline by Kyowa Hakko Kirin Co Ltd
  • Drug Addiction - Pipeline by MedRev Pharma
  • Drug Addiction - Pipeline by NLS Pharma Group
  • Drug Addiction - Pipeline by Omeros Corp
  • Drug Addiction - Pipeline by Opiant Pharmaceuticals Inc
  • Drug Addiction - Pipeline by Orexigen Therapeutics Inc
  • Drug Addiction - Pipeline by P2D Bioscience
  • Drug Addiction - Pipeline by Saniona AB
  • Drug Addiction - Pipeline by Savant HWP Inc
  • Drug Addiction - Pipeline by Stada Arzneimittel AG
  • Drug Addiction - Pipeline by Teva Pharmaceutical Industries Ltd
  • Drug Addiction - Pipeline by Zynerba Pharmaceuticals Inc
  • Nicotine Addiction - Pipeline by Addex Therapeutics Ltd
  • Nicotine Addiction - Pipeline by Astraea Therapeutics LLC
  • Nicotine Addiction - Pipeline by C4X Discovery Holdings PLC
  • Nicotine Addiction - Pipeline by Chronos Therapeutics Ltd
  • Nicotine Addiction - Pipeline by CV Sciences Inc
  • Nicotine Addiction - Pipeline by Hager Biosciences LLC
  • Nicotine Addiction - Pipeline by Heptares Therapeutics Ltd
  • Nicotine Addiction - Pipeline by Omeros Corp
  • Nicotine Addiction - Pipeline by Savant HWP Inc
  • Opium (Opioid) Addiction - Pipeline by Alkermes Plc
  • Opium (Opioid) Addiction - Pipeline by Aoxing Pharmaceutical Company Inc
  • Opium (Opioid) Addiction - Pipeline by Aquilus Pharmaceuticals Inc
  • Opium (Opioid) Addiction - Pipeline by BioCorRx Inc
  • Opium (Opioid) Addiction - Pipeline by BioDelivery Sciences International Inc
  • Opium (Opioid) Addiction - Pipeline by Camurus AB
  • Opium (Opioid) Addiction - Pipeline by Foresee Pharmaceuticals LLC
  • Opium (Opioid) Addiction - Pipeline by Heron Therapeutics Inc
  • Opium (Opioid) Addiction - Pipeline by Indivior Plc
  • Opium (Opioid) Addiction - Pipeline by INSYS Therapeutics Inc
  • Opium (Opioid) Addiction - Pipeline by Omeros Corp
  • Opium (Opioid) Addiction - Pipeline by Opiant Pharmaceuticals Inc
  • Opium (Opioid) Addiction - Pipeline by Orexigen Therapeutics Inc
  • Opium (Opioid) Addiction - Pipeline by Orexo AB
  • Opium (Opioid) Addiction - Pipeline by Pfizer Inc
  • Opium (Opioid) Addiction - Pipeline by Relmada Therapeutics Inc
  • Opium (Opioid) Addiction - Pipeline by Savant HWP Inc
  • Opium (Opioid) Addiction - Pipeline by Teva Pharmaceutical Industries Ltd
  • Opium (Opioid) Addiction - Pipeline by Titan Pharmaceuticals Inc
  • Opium (Opioid) Addiction - Pipeline by Zynerba Pharmaceuticals Inc
  • Alcohol Addiction - Dormant Projects
  • Drug Addiction - Dormant Projects
  • Nicotine Addiction - Dormant Projects
  • Opium (Opioid) Addiction - Dormant Projects
  • Alcohol Addiction - Discontinued Products
  • Drug Addiction - Discontinued Products
  • Nicotine Addiction - Discontinued Products
  • Opium (Opioid) Addiction - Discontinued Products

List of Figures

  • Number of Products under Development for Alcohol Addiction
  • Number of Products under Development by Companies, Alcohol Addiction
  • Number of Products under Development by Universities/Institutes, Alcohol Addiction
  • Number of Products under Development for Drug Addiction
  • Number of Products under Development by Companies, Drug Addiction
  • Number of Products under Development by Universities/Institutes, Drug Addiction
  • Number of Products under Development for Nicotine Addiction
  • Number of Products under Development by Companies, Nicotine Addiction
  • Number of Products under Development for Opium (Opioid) Addiction
  • Number of Products under Development by Companies, Opium (Opioid) Addiction
  • Number of Products under Development by Universities/Institutes, Opium (Opioid) Addiction
  • Number of Products by Top 10 Targets, Alcohol Addiction
  • Number of Products by Stage and Top 10 Targets, Alcohol Addiction
  • Number of Products by Top 10 Mechanism of Actions, Alcohol Addiction
  • Number of Products by Stage and Top 10 Mechanism of Actions, Alcohol Addiction
  • Number of Products by Routes of Administration, Alcohol Addiction
  • Number of Products by Stage and Routes of Administration, Alcohol Addiction
  • Number of Products by Molecule Types, Alcohol Addiction
  • Number of Products by Stage and Molecule Types, Alcohol Addiction
  • Number of Products by Top 10 Targets, Drug Addiction
  • Number of Products by Stage and Top 10 Targets, Drug Addiction
  • Number of Products by Top 10 Mechanism of Actions, Drug Addiction
  • Number of Products by Stage and Top 10 Mechanism of Actions, Drug Addiction
  • Number of Products by Routes of Administration, Drug Addiction
  • Number of Products by Stage and Routes of Administration, Drug Addiction
  • Number of Products by Molecule Types, Drug Addiction
  • Number of Products by Stage and Molecule Types, Drug Addiction
  • Number of Products by Top 10 Targets, Nicotine Addiction
  • Number of Products by Stage and Top 10 Targets, Nicotine Addiction
  • Number of Products by Top 10 Mechanism of Actions, Nicotine Addiction
  • Number of Products by Stage and Top 10 Mechanism of Actions, Nicotine Addiction
  • Number of Products by Stage and Routes of Administration, Nicotine Addiction
  • Number of Products by Molecule Types, Nicotine Addiction
  • Number of Products by Stage and Molecule Types, Nicotine Addiction
  • Number of Products by Top 10 Targets, Opium (Opioid) Addiction
  • Number of Products by Stage and Top 10 Targets, Opium (Opioid) Addiction
  • Number of Products by Top 10 Mechanism of Actions, Opium (Opioid) Addiction
  • Number of Products by Stage and Top 10 Mechanism of Actions, Opium (Opioid) Addiction
  • Number of Products by Routes of Administration, Opium (Opioid) Addiction
  • Number of Products by Stage and Routes of Administration, Opium (Opioid) Addiction
  • Number of Products by Molecule Types, Opium (Opioid) Addiction
  • Number of Products by Stage and Molecule Types, Opium (Opioid) Addiction
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • Addex Therapeutics Ltd
  • Adial Pharmaceuticals LLC
  • Aelis Farma SAS
  • Alkermes Plc
  • Aoxing Pharmaceutical Company Inc
  • Aphios Corp
  • Aquilus Pharmaceuticals Inc
  • Astraea Therapeutics LLC
  • BioCorRx Inc
  • BioDelivery Sciences International Inc
  • Bionex Pharmaceuticals LLC
  • Bioprojet SCR
  • C4X Discovery Holdings PLC
  • CV Sciences Inc
  • Camurus AB
  • Cerecor Inc
  • Chiesi Farmaceutici SpA
  • Chronos Therapeutics Ltd
  • Corcept Therapeutics Inc
  • Curemark LLC
  • Eli Lilly and Company
  • Embera NeuroTherapeutics Inc
  • Ethypharm SA
  • Euthymics Bioscience Inc
  • F. Hoffmann-La Roche Ltd
  • Foresee Pharmaceuticals LLC
  • H. Lundbeck A/S
  • Hager Biosciences LLC
  • Heptares Therapeutics Ltd
  • Heron Therapeutics Inc
  • INSYS Therapeutics Inc
  • Immunovaccine Inc
  • Indivior Plc
  • InterveXion Therapeutics LLC
  • Intra-Cellular Therapies Inc
  • Kinnov Therapeutics SAS
  • Kyorin Pharmaceutical Co Ltd
  • Kyowa Hakko Kirin Co Ltd
  • Lohocla Research Corp
  • MedRev Pharma
  • NLS Pharma Group
  • Omeros Corp
  • Opiant Pharmaceuticals Inc
  • Orexigen Therapeutics Inc
  • Orexo AB
  • P2D Bioscience
  • Pfizer Inc
  • Relmada Therapeutics Inc
  • SK Biopharmaceuticals Co Ltd
  • Saniona AB
  • Savant HWP Inc
  • Stada Arzneimittel AG
  • Teva Pharmaceutical Industries Ltd
  • Titan Pharmaceuticals Inc
  • Tonix Pharmaceuticals Holding Corp
  • VM Discovery Inc
  • XenoPort Inc
  • Zynerba Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll